Long non ‐coding RNA NORAD promotes the occurrence and development of non‐small cell lung cancer by adsorbing MiR‐656‐3p

ConclusionLncRNANORAD is capable of promoting the proliferation and migration of NSCLC cells, and its mechanism may be that it increases theAKT1 expression by adsorbing miR ‐656‐3p.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Conclusion: In conclusion, these results suggested that euscaphic acid G from G. longituba showed potential anticancer effects against lung cancer cells via inducing cell cycle arrest and apoptosis, at least partly, through NF-κB signaling pathways.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Zhou G, Xie J, Gao Z, Yao W Abstract MicroRNAs (miRNAs/miRs) are frequently differentially expressed in non-small cell lung cancer (NSCLC), and differential miRNAs expression may be closely associated with NSCLC genesis and development. Therefore, an in-depth investigation of the cancer-associated miRNAs that are crucial for NSCLC pathogenesis may provide effective therapeutic targets for patients with this aggressive malignant tumor type. The expression levels and roles of miR-877 have been well studied in hepatocellular carcinoma and renal cell carcinoma. However, the expression pattern and functions of ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Chang Z Abstract Non-small-cell lung cancer (NSCLC) is the leading type of cancer worldwide and sex determining region Y-box 2 (SOX2) has been implicated as an oncogene in various types of cancer. In the present study, SOX2 was positively associated with NSCLC stage and lymph node metastasis. Wound healing and Transwell assays demonstrated that knockdown of SOX2 inhibited A549 and H1299 cell migration. Furthermore, it was identified that knockdown of SOX2 inhibited epithelial-to-mesenchymal transition of NSCLC cells, which was demonstrated by increased expression of epithelial-cadherin and decreased expres...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Publication date: Available online 16 July 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Xiaoyun Liu, Wei Li, Yifan Zhang, Yong Jiang, Qianyu Zhao, Dafang ZhongAbstractAlflutinib, or known as AST2818, is an irreversible tyrosine kinase inhibitor that selectively inhibits EGFR mutations, especially T790M. At present, alflutinib has undergone phase II/III clinical trials for non-small cell lung cancer (NSCLC) treatment in China. The present study aimed to analye the pharmacokinetics of alflutinib and its active metabolite AST5902 in a plasma sample of NSCLC patient. A sensitive and highly selective ...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
ConclusionsFurther studies are warranted to establish appropriate eligible criteria and management strategies for Chinese populations.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
AbstractMonoclonal antibodies targeting PD-1 are used for treating NSCLC. To date, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been poorly investigated in the oncologic field. Here, we aimed at evaluating whether serum PCSK9 might represent a predictive factor for OS in older patients with advanced NSCLC under nivolumab treatment. Among 78 patients with advanced, pre-treated NSCLC previously enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 44 patients have been included in this sub-analysis due to the availability of serum samples for the measurement of PCSK9. Before each ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Authors: Samuelsen C, Lim J, Golembesky A, Shrestha S, Wang L, Griebsch I Abstract Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment. Materials and methods: This retrospective analysis used data from three large administrative claims databases in the United States: Truven MarketScan, IMS PharMetrics Plus and Optum Clinformatics Data Mart. Patients with diagnosis codes of lung cancer treated with afatinib or erlotinib were include...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
To the Editor: We commend Zhang et  al1 for their recent systematic review of cardiac dose parameters in radiation therapy for non-small cell lung cancer (NSCLC). The authors rightly point out the limitations with the current literature on this topic: study heterogeneity, retrospective data analysis, and multiplicity of testing. We would also argue that the research into cardiac toxicity in NSCLC radiation therapy lacks well-defined hypotheses and research questions. Nevertheless, we do not agree with the authors that no conclusions regarding cardiac dose parameters can be drawn from these studies.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
Local consolidative therapy (LCT) in addition to systemic therapy for patients with oligometastatic non-small cell lung cancer (NSCLC) is an evolving treatment strategy. We sought to identify whether the biologically effective dose (BED) of radiation (RT) to the primary tumor predicted for improved local control, progression-free survival (PFS) and overall survival (OS) among non-small cell lung cancer (NSCLC) patients presenting with oligometastatic disease at diagnosis.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Publish Only Source Type: research
Metastatic lung cancer has long represented a therapeutic challenge, with treatment primarily consisting of systemic chemotherapy, with limited long-term survival. Patients with limited sites ( ≤ 5) of metastatic disease, known as oligometastatic disease, may derive improved outcomes from aggressive local therapy. Stereotactic ablative radiation therapy (SABR) represent a promising new method of conformal aggressive treatment to oligometastic disease. Herein we report analysis of a prosp ective multi-center phase II trial assess the safety and feasibility of SABR for oligometastatic non-small-cell lung cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Publish Only Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer